Targeting the hypoxia-inducible factor-1 alpha-exoVEGF axis in tumor-associated macrophages overcomes Bacillus Calmette-Guérin immunotherapy resistance

Yuyang Hou , Yuxi Wang , Qiong Wu , Wenjing Du , Shanzhu Guo , Xinyu Chai , Yinan Wang , Huixin Liang , Hongyan Yuan , Jun Li , Dongmei Yan

Interdisciplinary Medicine ›› 2026, Vol. 4 ›› Issue (1) : e70063

PDF
Interdisciplinary Medicine ›› 2026, Vol. 4 ›› Issue (1) :e70063 DOI: 10.1002/inmd.70063
RESEARCH ARTICLE
Targeting the hypoxia-inducible factor-1 alpha-exoVEGF axis in tumor-associated macrophages overcomes Bacillus Calmette-Guérin immunotherapy resistance
Author information +
History +
PDF

Abstract

Bacillus Calmette-Guérin (BCG) immunotherapy is limited by resistance in ∼50% of patients, linked to tumor microenvironment (TME) angiogenesis. The work explored if BCG-activated tumor-associated macrophages (TAMs) drive angiogenesis via hypoxia-inducible factor-1α (HIF-1α) to impair BCG efficacy. Results demonstrated that macrophages stimulated with BCG significantly enhanced the proliferation, migration, and tube formation of endothelial cells. Further mechanistic studies revealed that this pro-angiogenic effect was mediated through the activation of the NF-κB, PI3K/AKT and p38/MAPK signaling pathways. Activation of these pathways subsequently led to the upregulated expression of HIF-1α and vascular endothelial growth factor A (VEGFA). Critically, HIF-1α deficiency in macrophages effectively inhibited BCG-induced angiogenesis without exerting a significant impact on the infiltration of CD8+ T cells or B cells. Additionally, BCG stimulation enhanced the secretion of VEGF encapsulated in exosomes in an HIF-1α-dependent manner, and these VEGF-enriched exosomes further facilitated the activation of endothelial cell functions. In conclusion, the present study confirms that BCG can promote tumor angiogenesis by activating macrophages to induce the release of exosome-derived VEGF through an HIF-1α-dependent pathway. Targeting the HIF–1α-exosome-derived VEGF (HIF-1α–exoVEGF) axis holds promise as a potential strategy to overcome BCG resistance and improve its therapeutic efficacy.

Keywords

angiogenesis / BCG / exosome / HIF-1α / macrophage / VEGF

Cite this article

Download citation ▾
Yuyang Hou, Yuxi Wang, Qiong Wu, Wenjing Du, Shanzhu Guo, Xinyu Chai, Yinan Wang, Huixin Liang, Hongyan Yuan, Jun Li, Dongmei Yan. Targeting the hypoxia-inducible factor-1 alpha-exoVEGF axis in tumor-associated macrophages overcomes Bacillus Calmette-Guérin immunotherapy resistance. Interdisciplinary Medicine, 2026, 4(1): e70063 DOI:10.1002/inmd.70063

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

N. M. G. P. de Queiroz, F. V. Marinho, A. C. V. S. C. de Araujo, J. S. Fahel, S. C. Oliveira, Sci. Rep. 2021, 11, 15648.

[2]

Y. W. Chen, L. Zhang, H. S. Shi, Z. X. Shen, D. Huang, S. Tang, Y. Y. He, G. L. Wang, H. L. Pan, Z. L. Wang, Biochem. Biophys. Res. Commun. 2025, 745, 151215.

[3]

S. Sloot, O. M. Rashid, A. A. Sarnaik, J. S. Zager, Cancer Control 2016, 23, 12.

[4]

A. Morales, D. Eidinger, A. W. Bruce, J. Urol. 1976, 116, 180.

[5]

J. H. Stewart, E. A. Levine, Expert Rev. Anticancer Ther. 2011, 11, 1671.

[6]

Q. Liu, Y. Tian, X. Zhao, H. Jing, Q. Xie, P. Li, D. Li, D. Yan, X. Zhu, Mol. Cells 2015, 38, 886.

[7]

Y. Tian, Y. T. Guo, P. Zhu, D. X. Zhang, S. S. Liu, M. Y. Tang, Y. X. Wang, Z. Jin, D. Li, D. M. Yan, G. Y. Li, X. Zhu, Aging 2019, 11, 8623.

[8]

Y. Tian, Z. Jin, P. Zhu, S. S. Liu, D. X. Zhang, M. Y. Tang, Y. X. Wang, D. Li, D. M. Yan, G. Y. Li, X. Zhu, Exp. Cell Res. 2019, 384, 111590.

[9]

M. R. Saban, T. J. Sferra, C. A. Davis, C. Simpson, A. Allen, J. Maier, B. Fowler, N. Knowlton, L. Birder, X. R. Wu, R. Saban, Am. J. Physiol. Renal Physiol. 2010, 299, F1245.

[10]

Z. Lei, Y. M. Luo, J. L. Lu, Q. G. Fu, C. Wang, Q. Chen, Z. W. Zhang, L. Zhang, Cancer Gene Ther. 2025, 32, 198.

[11]

S. L. Zou, Q. Y. Tong, B. W. Liu, W. Huang, Y. Tian, X. H. Fu, Mol. Cancer 2020, 19, 145.

[12]

P. Carmeliet, R. K. Jain, Nature 2011, 473, 298.

[13]

X. G. Wu, C. F. Zhou, Y. M. Zhang, R. M. Yan, W. F. Wei, X. J. Chen, H. Y. Yi, L. J. Liang, L. S. Fan, L. Liang, S. Wu, W. Wang, Angiogenesis 2023, 26, 201.

[14]

E. I. Buzas, Nat. Rev. Immunol. 2023, 23, 236.

[15]

Z. J. Xu, S. S. Zeng, Z. C. Gong, Y. L. Yan, Mol. Cancer 2020, 19, 160.

[16]

M. M. Zegeye, B. Andersson, A. Sirsjö, L. U. Ljungberg, Cells 2020, 9, 1414.

[17]

M. Simons, E. Gordon, L. Claesson-Welsh, Nat. Rev. Mol. Cell Biol. 2016, 17, 611.

[18]

Z. Zhang, L. Yao, J. H. Yang, Z. K. Wang, G. Du, Mol. Med. Rep. 2018, 18, 3547.

[19]

J. H. Park, J. Yoon, B. Park, Phytomedicine 2016, 23, 1716.

[20]

H. Yu, B. Wang, Z. H. Li, K. B. Liu, W. Y. Chen, S. Y. Zhao, Y. Zhou, G. Y. Wang, Y. Q. Zhou, Y. M. Chen, H. S. Chen, Y. N. Lai, Q. Wang, J. P. Wang, B. T. Ni, D. P. Zhang, C. M. Pan, Y. C. He, L. Q. Li, Mater. Today Bio 2025, 32, 101762.

[21]

A. M. Kamat, R. J. Sylvester, A. Böhle, J. Palou, D. L. Lamm, M. Brausi, M. Soloway, R. Persad, R. Buckley, M. Colombel, J. A. Witjes, J. Clin. Oncol. 2016, 34, 1935.

[22]

M. E. Ritchie, B. Phipson, D. Wu, Y. F. Hu, C. W. Law, W. Shi, G. K. Smyth, Nucleic Acids Res. 2015, 43, e47.

[23]

C. Sánchez-Rodríguez, K. P. Cruces, J. R. Ayora, E. Martín-Sanz, R. Sanz-Fernández, Vaccine 2017, 35, 6395.

[24]

A. Olsson, J. Nakhlé, A. Sundstedt, P. Plas, A. L. Bauchet, V. Pierron, L. Bruetschy, A. Deronic, M. Törngren, D. Liberg, F. Schmidlin, T. Leanderson, J. Immunother. Cancer 2015, 3, 53.

[25]

X. Huang, P. F. Liang, B. M. Jiang, P. H. Zhang, W. C. Yu, M. T. Duan, L. Guo, X. Cui, M. T. Huang, X. Y. Huang, Life Sci. 2020, 259, 118246.

[26]

J. Drachneris, M. Morkunas, M. Fabijonavicius, A. Cekauskas, F. Jankevicius, A. Laurinavicius, Int. J. Mol. Sci. 2024, 25, 4776.

[27]

J. W. Davis, S. I. Sheth, M. J. Doviak, P. F. Schellhammer, J. Urol. 2002, 167, 494.

[28]

F. Claps, N. Pavan, L. Ongaro, D. Tierno, G. Grassi, C. Trombetta, G. Tulone, A. Simonato, R. Bartoletti, L. S. Mertens, B. W. G. van Rhijn, M. C. Mir, B. Scaggiante, Int. J. Mol. Sci. 2023, 24, 12596.

[29]

S. A. Boorjian, M. Alemozaffar, B. R. Konety, N. D. Shore, L. G. Gomella, A. M. Kamat, T. J. Bivalacqua, J. S. Montgomery, S. P. Lerner, J. E. Busby, M. Poch, P. L. Crispen, G. D. Steinberg, A. K. Schuckman, T. M. Downs, R. S. Svatek, J. Mashni, B. R. Lane, T. J. Guzzo, G. Bratslavsky, L. I. Karsh, M. E. Woods, G. Brown, D. Canter, A. Luchey, Y. Lotan, T. Krupski, B. A. Inman, M. B. Williams, M. S. Cookson, K. A. Keegan, G. L. Andriole, A. I. Sankin, A. Boyd, M. A. O'Donnell, D. Sawutz, R. Philipson, R. Coll, V. M. Narayan, F. P. Treasure, S. Yla-Herttuala, N. R. Parker, C. P. N. Dinney, Lancet Oncol. 2021, 22, 107.

[30]

A. R. H. Shepherd, E. Shepherd, N. R. Brook, Cochrane Database Syst. Rev. 2017, 3, CD012112.

[31]

M. Voskoboynik, S. Rudman, H. T. Arkenau, S. Hughes, S. Chowdhury, BJU Int. 2016, 117, 721.

[32]

H. Ohno, S. Mano, N. Katagiri, R. Ogur, K. Miyazaki, K. Ito, Y. Sekiya, K. Inoue, A. Masuda, A. Tsuzuku, F. Asano, T. Hirashita, T. Hayashi, Pharmazie 2022, 77, 248.

[33]

G. Sonpavde, J. Bellmunt, Nat. Rev. Urol. 2016, 13, 306.

[34]

D. P. Petrylak, S. T. Tagawa, M. Kohli, A. Eisen, C. Canil, S. S. Sridhar, A. Spira, E. Y. Yu, J. M. Burke, D. Shaffer, C. X. Pan, J. J. Kim, J. B. Aragon-Ching, D. I. Quinn, N. J. Vogelzang, S. Tang, H. Zhang, C. T. Cavanaugh, L. Gao, J. S. Kauh, R. A. Walgren, K. N. Chi, J. Clin. Oncol. 2016, 34, 1500.

[35]

M. Shen, X. Ren, Cancer Lett. 2018, 431, 115.

[36]

Y. T. Zhang, Z. C. Hao, P. F. Wang, Y. Xia, J. H. Wu, D. M. Xia, S. Fang, S. G. Xu, Cell Prolif. 2019, 52, e12570.

[37]

Q. Zhang, A. P. da Cunha, S. Li, Q. Hao, V. Kainz, Q. Huang, H. Y. Wu, Cytokine 2019, 113, 238.

[38]

A. Sánchez-Navarro, R. Pérez-Villalva, A. R. Murillo-de-Ozores, M. A. Martínez-Rojas, J. R. Rodríguez-Aguilera, N. González, M. Castañeda-Bueno, G. Gamba, F. Recillas-Targa, N. A. Bobadilla, Sci. Rep. 2021, 11, 8769.

[39]

H. Z. Guo, Z. Y. Li, B. Xiao, R. C. Huang, Biol. Direct 2024, 19, 43.

[40]

Y. H. Yang, Z. Y. Guo, W. W. Chen, X. F. Wang, M. Cao, X. Han, K. D. Zhang, B. W. Teng, J. Cao, W. D. Wu, P. Cao, C. Huang, Z. J. Qiu, Mol. Ther. 2021, 29, 1226.

[41]

G. J. Luo, Z. K. Zhou, Z. M. Cao, C. X. Huang, C. Li, X. X. Li, C. Deng, P. F. Wu, Z. N. Yang, J. Y. Tang, L. M. Qing, Arch. Biochem. Biophys. 2024, 751, 109822.

[42]

J. S. Harding, M. Herbath, Y. L. Chen, A. Rayasam, A. Ritter, B. Csoka, G. Hasko, I. P. Michael, Z. Fabry, A. Nagy, M. Sandor, Cell Rep. 2019, 27, 2119.

[43]

K. K. Liu, L. N. Wang, J. Peng, Y. Lyu, Y. M. Li, D. Y. Duan, W. Y. Zhang, G. J. Wei, T. P. Li, Y. J. Niu, Y. Zhao, Adv. Mater. 2024, 36, 2310735.

[44]

W. Xu, Z. Liu, J. Wang, K. Jin, L. L. Yue, L. Yu, L. Q. Niu, Q. Q. Dou, J. L. Liu, Y. Z. Zhang, X. H. Zhu, Y. H. Wu, J. Colloid Interface Sci. 2025, 682, 608.

[45]

Z.-X. Liao, J. Wang, Food Med. Homol. 2024, 1, 9420025.

[46]

N. O. Dogan, E. Suadiye, P. Wrede, J. Lazovic, C. B. Dayan, R. H. Soon, A. Aghakhani, G. Richter, M. Sitti, Adv. Healthcare Mater. 2024, 13, 2400711.

[47]

V. D. Nguyen, H. K. Min, H. Y. Kim, J. Han, Y. H. Choi, C. S. Kim, J. O. Park, E. Choi, ACS Nano 2021, 15, 8492.

RIGHTS & PERMISSIONS

2025 The Author(s). Interdisciplinary Medicine published by Wiley-VCH GmbH on behalf of Nanfang Hospital, Southern Medical University.

PDF

4

Accesses

0

Citation

Detail

Sections
Recommended

/